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Abstract
Wepresent a follow-up case report of a 33-year-old ladywith juvenile onset arthritis who developed halo naevi while on treatment
with tocilizumab. This case report describes the development of halo naevi, vitiligo and diffuse alopecia areata associated with
tocilizumab therapy following infectionwithMethicillin-resistant Staphylococcus aureus (MRSA) andPanton–Valentine leukocidin
positivity. This is the ﬁrst case that describes these events and supports previous theories on cellular and humoral immunity as
causative factors. The regression of melanocytes during treatment with tocilizumab could also implicate IL-6 and sIL-6R as future
targets in the treatment of melanoma through its direct effect of melanocytic cytotoxicity, which supports previous studies.
INTRODUCTION
We present a follow-up case report of a 33-year-old lady with ju-
venile onset arthritis who developed halo naevi at the site of
every mole while on treatment with tocilizumab (Fig. 1) [1].
CASE REPORT
Twentyyears followingdiagnosis of juvenile onset arthritis, ourpa-
tient was commenced on tocilizumab 8mg/kg fortnightly. Shewas
taking no other medication other than lanzoprazole and iburpofen
as required. Three years later, shewent on to develop recurrent ab-
scesses in her axilla requiring incision and drainage. Swabs con-
ﬁrmed Methicillin-resistant Staphylococcus aureus (MRSA) and
Panton–Valentine leukocidin (PVL) positivity. Tocilizumab was
withheld for 6 months while the abscesses healed.
Within 2 months of recommencing tocilizumab at 8 mg/kg
4 weekly, haloes formed around her naevi and dermatology re-
view document classical halo naevi at the site of every naevus
on her body. A thorough skin and eye examination excluded
any underlying malignant melanoma. A skin biopsy was carried
out, which demonstrated a benign intradermal naevus. Tocilizu-
mabwas withheld brieﬂy, and the patient received phototherapy
but failed to respond. Tocilizumab was restarted for disease con-
trol, and the patient went on to develop patches of vitiligo on her
torso. Therefore, tocilizumab was discontinued and treatment
switched to abatacept. On discontinuing tocilizumab, there was
no further progression of depigmentation. Having failed abata-
cept (infusion reaction) and later certolizumab (primary non-
response), tocilizumab was restarted 18 months later. While
awaiting to restart tocilizumab, the patient was commenced on
oral prednisolone, which was weaned down with regain of dis-
ease control. After 6 months of therapy, the patient reported
loss of her eye lashes, eye brows and hair loss. A diagnosis of dif-
fuse alopecia areata was made following dermatology review.
DISCUSSION
IL-6 is a pleiotropic cytokine that regulates the immune response.
It is involved in autoimmunity by altering the balance between
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Th17 cells and Treg [2]. IL-6 is also involved in local inﬂammation
leading to joint destruction and is thought to mediate many of
the systemic inﬂammatory signs and symptoms related to
rheumatoid arthritis. It exerts its biological activities via an IL-
6-speciﬁc receptor and a signal transducer, gp130. The receptor
exists in two forms: a transmembrane form and a soluble form
(sIL-6R). Under physiological conditions, IL-6 is thought to act
in a paracrine fashion. If IL-6 levels exceed the levels of sIL-6R
and gp130, IL-6 can act systemically [3].
Tocilizumab is a humanized anti-IL6 receptor monoclonal
antibody that blocks transmembrane as well as sIL-6R.
This case was originally reported by Kuet and Goodﬁeld [1]
and is the ﬁrst to describe halo naevi with tocilizumab therapy.
This follow-up case report is the ﬁrst case to describe the devel-
opment of vitiligo and diffuse alopecia areata secondary to toci-
lizumab therapy.
Halo naevi are common benign skin lesions that represent
melanocytic naevi in which an inﬂammatory inﬁltrate develops,
resulting in a zone of depigmentation surrounding the naevus.
The aetiology is unknown, although halo naevi are thought to
share a similar autoimmune pathway to vitiligo.
Diffuse alopecia areata is a variant characterized by inﬂam-
matory-induced hair loss over a large scalp area without bald
patches and has an unclear aetiology. Studies suggest that the
autoimmune target may be related to the melanin pigment sys-
tem and/or melanocytes.
The exact immune process involved in the destruction ofmel-
anocytes during the development of vitiligo is yet to be deter-
mined, although there is strong evidence of cellular immunity
involvement and the role of IL-6.
IL-6 concentrations have been found to be signiﬁcantly higher
in patients with vitiligo [4], and IL-6 can induce the expression of
ICAM-1 on melanocytes, thereby facilitating leucocyte–melano-
cyte attachment and immunological cytotoxicity. IL-6 also
causes an imbalance of T regs and Th17, and this dysregulation
may also contribute to the pathogenesis of vitiligo.
Tocilizumab therapy blocks IL-6R, thereby inhibiting the con-
sumption of IL-6 by normal receptors, leading to an increase in
serum IL-6 [5]. This increase in IL-6 could therefore act systemic-
ally andhave a direct effect onmelanocytes or cause a further im-
balance of T regs and Th17 leading to vitiligo.
The role of IL-6 in alopecia areata is less well documented, al-
though higher levels have been found in patchy alopecia areata
[6]. There have been case reports of diffuse alopecia areata occur-
ring following anti-TNF therapy and chemotherapy, and the
pathogenesis is likely to involve a T-cell autoimmune-mediated
process triggered by endogenous or exogenous stimuli that sus-
tains an inﬂammatory reaction that leads to hair loss.
Cross-reacting antigens from infecting organismsmay be im-
plicated in vitiligo, and our patient only developed depigmen-
tation on resuming treatment following infection with MRSA
with PVL positivity. This infection may have been signiﬁcant in
the development of halo naevi, vitiligo and alopecia areata in
combination with the cytokine disturbances created by
tocilizumab.
This case report provides insights into the pathogenesis of
halo naevi, vitiligo and diffuse alopecia areata and supports pre-
vious theories on cellular and humoral immunity as causative
factors.
The regression of melanocytes during treatment with tocili-
zumab provides evidence for IL-6 and sIL-6R as future targets in
the treatment ofmelanoma through its direct effect ofmelanocy-
tic cytotoxicity supporting previous studies [7, 8].
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